TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04524975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-008-0045
Description: CD-008-0045 20 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-008-0045
Description: CD-008-0045 20 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT01986205

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen (USP oxygen \>99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Minimal pressure air
Description: Room air delivered in a hyperbaric chamber with minimal pressurization.
Study: NCT02350829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance sequence T1 mapping
Description: Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance sequence T1 mapping
Description: Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance sequence T1 mapping
Description: Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
Study: NCT00089180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal T4N5 lotion
Description: Given topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02747628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal therapeutic system- nicotine.
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal therapeutic system- melatonin.
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
Study: NCT03279237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: May help shrink tumor before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: May help shrink tumor before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: May help shrink tumor before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: May help shrink tumor before surgery.
Study: NCT02771587

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol and energy drink
Description: Multiple oral dose of alcohol Multiple oral dose of energy drink

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Multiple oral dose of alcohol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy drink
Description: Multiple oral dose of energy drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
Study: NCT01245361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3 mg/kg wk 0,2,6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: Group II : Placebo wk 0,2,6
Study: NCT03018665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIAsp30
Description: subcutaneous injection，fit dosage twice a day in three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: oral，0.85g，twice a day in three months
Study: NCT03279237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel may stop cancer cells from growing and spreading.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: May help shrink tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin may stop cancer cells from growing.
Study: NCT04418037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System(DHFS)
Description: We will investigate the feasibility of using the DHFS in hospitalized individuals living with HIV to support ARV adherence.
Study: NCT02595229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronator quadratus repair
Description: Suturing of the pronator quadratus muscle
Study: NCT02810002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental infantry boot - DEFINITE-REGULATOR
Description: Training: infantry basic training in the experimental boots

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control infantry boot
Description: Training: infantry basic training in the control boots
Study: NCT04392011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam HCl
Description: Oral syrup, 2 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan HBr
Description: Oral liquid capsules, 15 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
Study: NCT05106803

Intervention type: DRUG
Intervention: ciprofloxacin
Description: Antibiotics used in vitro n the study
Study: NCT00774189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin 250 mg tablets
Study: NCT04392011

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
Study: NCT03749902

Intervention type: DRUG
Group type: OTHER
Intervention: Oral misoprostol
Description: * An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~* The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~* If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~* In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: * Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~* The oxytocin group will not receive misoprostol after the membranes have ruptured.
Study: NCT04395768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
Study: NCT00774189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin 250 mg tablets
Study: NCT03372876

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein and carbohydrate supplementation
Description: Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and carbohydrate supplementation
Description: Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
Study: NCT00726830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine sulfate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone hydrochloride
Description: Given orally
Study: NCT04395768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Citrate
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study: NCT03861507

Intervention type: DEVICE
Group type: OTHER
Intervention: Prostate Brachytherapy
Description: High dose - rate (HDR) brachytherapy
Study: NCT04395768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Citrate
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study: NCT03030261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
Study: NCT02793635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Powered Exoskeleton
Description: Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
Study: NCT02868437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine self-cross-linked hyaluronic acid gel
Description: intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
Study: NCT03108235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOM-HEMP
Description: a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOM-HEMP with smartphone app
Description: a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse. In addition, participants will receive a smartphone app.~The smartphone will be used to monitor their health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
Study: NCT02947451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once.
Study: NCT02281539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromotus
Study: NCT04143607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK120067
Description: ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib 250 mg
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT00003509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04063579

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization
Description: Imaging, blood tests, LV pressure measurement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization
Description: Imaging, blood tests, LV pressure measurement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)
Description: Imaging and Blood tests
Study: NCT02168920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg/day
Description: Once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/day
Description: Once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg/day
Description: Once daily for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0 mg/day)
Description: Once daily for 10 weeks
Study: NCT03250598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: 50 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: 5 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: 200 mg single-dose
Study: NCT00541957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavior therapy
Description: 10 sessions over 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication prescribed by PCP
Description: Can include any antidepressant medication

Intervention type: DRUG
Group type: OTHER
Intervention: Medication prescribed by PCP
Description: Can include any antidepressant medication
Study: NCT00904241

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02947451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
Study: NCT03671863

Intervention type: OTHER
Intervention: Invasive analysis (caryotype, CGH array)
Description: Invasive analysis (caryotype, CGH array)

Intervention type: OTHER
Intervention: Prenatal management
Description: Prenatal management
Study: NCT03340740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 1 MG/ML
Description: Cetirizine oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Similar-appearing liquid to cetirizine oral suspension
Study: NCT02752308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilute epinephrine injection
Description: Injection of 1/100000 epinephrine solution along all incision lines
Study: NCT02487446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
Study: NCT02613507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02487446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (umeclidinium/vilanterol)
Description: Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (umeclidinium/vilanterol)
Description: Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (QVA149)
Description: Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (QVA149)
Description: Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Study: NCT00988585

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA 600
Description: EPA 600 mg/day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA 1800
Description: 1800 mg/day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 600 mg/day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: 600 mg/day for 6 weeks
Study: NCT03423459

Intervention type: DEVICE
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement

Intervention type: DEVICE
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement